Immuron Gets Euro Patent on Drug Composition to Treat Clostridioides difficile

 Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease.

Notification of the decision to grant European Patent 14784945.9, entitled “Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease,” was formally received yesterday, and grant of this application will be published in the European Patent Bulletin on 25 January 2023 under European Patent No. 2986316. The company previously reported it had received notification from the European Patent Office of the intent to grant in July last year (ASX announcement July 7, 2022).

The European registration adds to Immuron's patent position for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease in Australia, New Zealand and the United States.

https://finance.yahoo.com/news/immuron-receives-european-patent-drug-121000907.html

Pfizer cut to Equal Weight from Overweight by Wells Fargo

 Target to $50 from $54

https://finviz.com/quote.ashx?t=PFE&ty=c&ta=1&p=d

TC Bio in Collaboration to Advance Gamma Delta T Cells in Oncology

  TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announces a strategic collaboration with The University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.

The collaboration brings together MD Anderson's clinical trial infrastructure and the translational research expertise of its immunotherapy platform with the clinical data of TC BioPharm's targeted gamma-delta T cell oncology pipeline. Under the terms of the three-year agreement, the research teams will work together on both preclinical and clinical studies to evaluate the potential for gamma-delta T cell therapies and to better understand the behaviors of these cells in patients.  The collaborators will form a six-person steering committee to drive the development of both the data set and subsequent assays for each study.

https://finance.yahoo.com/news/tc-biopharm-announces-strategic-collaboration-133000172.html

Brookdale cut to Hold from Buy by Stifel

 Target to $4 from $5

https://finviz.com/quote.ashx?t=BKD&ty=c&ta=1&p=d

Tenet Healthcare gains as David Einhorn's Greenlight takes stake

 Tenet Healthcare (NYSE:THC) rose 1% after David Einhorn's Greenlight Capital took a medium-sized stake in the hospital operator.

Greenlight took the position in Q4, according to copy of Greenlight's Q4 investor letter from Tuesday viewed by Seeking Alpha. Greenlight acquired the shares from late December through the beginning of January for an average price of $48.61 a share.

"During 2022, the company lowered its guidance due to COVID and inflationary headwinds, resulting in its shares declining by more than 50% year-to-date through late October," according to the letter. "We believe this pullback offered an attractive opportunity to participate in the company’s transformation, as we expect its ASC growth to remain strong and its now smaller hospital portfolio to improve from both a cost and volume perspective."

The Greenlight Capital funds returned 36.6% in 2022, net of fees and expenses, compared to an 18.1% loss for the S&P 500 index, according to the Q4 letter.

The significant long winners in 2022 were Atlas Air Worldwide (AAWW), CONSOL Energy (CEIX), Siltstone Capital (private), Teck Resources (TECK) and Twitter (TWTR).

News of the Einhorn stake in Tenet (THC) was earlier reported by Bloomberg.

Tenet (THC) on Tuesday announced it plans to report Q4 results on Feb. 9.

https://www.tradingview.com/news/seeking_alpha:4ece74190094b:0-tenet-healthcare-gains-as-david-einhorn-s-greenlight-takes-stake-update/

Inogen cut to Market Perform by Blair

 From Outperform

https://finviz.com/quote.ashx?t=INGN&ty=c&ta=1&p=d

Amylyx in Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm

 Neopharm gains exclusive rights to commercialize AMX0035 in Israel, Gaza, West Bank, and the Palestinian Authority

- Agreement marks Amylyx’ first distribution partnership since AMX0035 regulatory approvals and commercial launches in the U.S. and Canada

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm will commercialize, subject to regulatory review and approval, AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian Authority.

https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-exclusive-amx0035-070000794.html